News Release
Simply Solventless Concentrates announces new VP as company plans 2024 products launch
Simply Solventless Concentrates
Simply Solventless Concentrates CEO Jeff Swainson joins Steve Darling from Proactive to share exciting updates regarding the company's upcoming activities. Simply Solventless Concentrates anticipates a busy month ahead, with approximately $1.25 million in purchase orders lined up from Alberta and Ontario. Additionally, the company is set to launch six third-party branded products in Alberta and one in Ontario, further expanding its market presence. Swainson underscored the importance of strategic leadership in supporting the company's growth trajectory. To this end, Simply Solventless Concentrates announced the appointment of Jeff Lawrence to the position of Vice President, Marketing & Sales. Lawrence brings over 30 years of experience in industrial and consumer packaged goods, including five years in the cannabis industry. With a proven track record of driving sales growth and propelling startups through strategic development, team building, and effective leadership, Lawrence is poised to make a significant impact on the company's sales and marketing initiatives. Swainson highlighted Lawrence's previous role as National Director of Sales at Dycar Pharmaceuticals, where he played a key role in overseeing the launch of four brands and scaling store listings from 70 to over 2,200 across five provinces. Lawrence's extensive experience and leadership acumen make him a valuable addition to the Simply Solventless Concentrates team, positioning the company for continued success and expansion in the competitive cannabis market. With a robust pipeline of purchase orders and new product launches on the horizon, Simply Solventless Concentrates is primed for growth under Lawrence's leadership. Stay tuned for further updates as the company continues to execute its strategic initiatives and capitalize on emerging opportunities in the cannabis industry. Contact Details Proactive North America Proactive North America +1 604-688-8158 NA-editorial@proactiveinvestors.com
February 20, 2024 10:29 AM Eastern Standard Time
Video
News Release
CervoMed appoints drug development veteran Dr. Joshua Boger as Chairman of the Board
CervoMed
CervoMed Inc CEO John Alam joined Steve Darling from Proactive to announce a significant addition to the company's leadership team. CervoMed has appointed Joshua Boger to its Board of Directors as Chair, leveraging his wealth of experience in drug development and biopharmaceutical leadership to drive the company's strategic initiatives forward. Dr. Boger is a seasoned industry veteran with over 40 years of experience, renowned for his innovative approach to science and proven track record as a business executive. Currently serving as Executive Chairman of Alkeus Pharmaceuticals, Dr. Boger brings invaluable insights and expertise to CervoMed. Alam elaborated on the significance of Dr. Boger's appointment and the pivotal phase the company is entering, with topline data from the RewinD-LB Phase 2b clinical trial evaluating neflamapimod in dementia with Lewy bodies (DLB) expected in the second half of 2024. Neflamapimod, an investigational orally administered small molecule brain penetrant that inhibits p38MAP kinase alpha, holds immense promise in addressing synaptic dysfunction, particularly in the basal forebrain cholinergic system, which is most impacted in DLB. Drawing from preclinical studies and clinical trials involving over 300 participants, Alam highlighted neflamapimod's favorable safety profile and its significant impact on dementia severity as demonstrated in the AscenD-LB Phase 2a clinical study. These promising results underscore the potential of neflamapimod to address the unmet medical needs in DLB and pave the way for transformative treatment options. The appointment of Dr. Boger and the advancements in CervoMed's clinical trials signify a significant milestone in the company's mission to develop innovative therapies for neurodegenerative diseases. With a visionary leadership team and a promising pipeline of treatments, CervoMed is poised to make a meaningful impact on the lives of patients and caregivers affected by DLB and related conditions. Stay tuned for further updates as CervoMed continues its journey towards advancing neurological healthcare. Contact Details Proactive North America Proactive North America +1 604-688-8158 NA-editorial@proactiveinvestors.com
February 20, 2024 10:22 AM Eastern Standard Time
Video
News Release
Cloud DX secures key partnership with Sanrai International for worldwide distribution
Cloud DX
Cloud DX CEO Robert Kaul joined Steve Darling from Proactive to announce a new Partnership Agreement with New York-based Sanrai International. Sanrai International, a leading medical device distribution company with a global presence, will now market and resell the Cloud DX Connected Health platform across more than 65 countries. Kaul highlighted the significance of this partnership, emphasizing Sanrai's extensive customer and sub-distributor network, which spans Latin America, Africa, the Middle East, Asia, and beyond. The focus of this collaboration will be on addressing chronic disease management and post-surgical recovery, leveraging Cloud DX's innovative Connected Health products and services. With the partnership in place, both Cloud DX and Sanrai aim to equalize access to innovative medical devices, particularly in the areas of chronic illness and post-surgical recovery. Kaul also mentioned that Cloud DX has already announced over $2.5 million CAD in new business in 2024, reflecting the company's continued growth and market expansion efforts. Contact Details Proactive North America Proactive North America +1 604-688-8158 NA-editorial@proactiveinvestors.com
February 20, 2024 10:06 AM Eastern Standard Time
Video
News Release
Filament Health announces FDA opening of IND application for substance abuse disorder
Filament Health Corp
Filament Health CEO Ben Lightburn joined Steve Darling from Proactive to share the groundbreaking news that the U.S. Food and Drug Administration (FDA) has given its approval for the Investigational New Drug application for PEX010, Filament Health's botanical psilocybin drug candidate designed for the treatment of Substance Use Disorders. This development paves the way for Filament Health to commence research activities in the United States, focusing on the potential use of their botanical psilocybin drug candidate in addressing substance use disorders, including those involving opioids. Lightburn went on to explain that the IND-opening protocol had previously been submitted to Health Canada and had received the department's no-objection status, underlining the company's commitment to adhering to rigorous regulatory standards on both sides of the border. Moreover, Lightburn highlighted the extensive scope of research and collaboration surrounding PEX010. Currently, a network of 24 research institutions and licensing partners across Canada, the USA, Europe, and Israel is actively studying PEX010 for various conditions. These include but are not limited to alcohol use disorder, depression, and coma, showcasing the versatile potential of this botanical psilocybin drug candidate in addressing a wide range of medical conditions. The acceptance of the IND application by the FDA marks a pivotal moment in Filament Health's journey, offering a pathway for innovative and potentially transformative treatments for substance use disorders. It also underscores the company's global reach and collaborative efforts in advancing the field of psychedelic medicine. This milestone is a testament to the commitment of Filament Health to research and develop solutions that hold promise for individuals struggling with these challenging conditions. Contact Details Proactive North America Proactive North America +1 604-688-8158 NA-editorial@proactiveinvestors.com
February 20, 2024 09:40 AM Eastern Standard Time
Video
News Release
Hemogenyx Pharmaceuticals achieves breakthrough with HEMO-CAR-T program, CBR platform
HemoGenyx Pharmaceuticals
Hemogenyx Pharmaceuticals PLC CEO Dr Vladislav Sandler and non-executive director Peter Redmond joined Proactive's Stephen Gunnion after the company pioneering breakthrough treatments for life-threatening diseases, including blood and solid cancers, achieved a number of significant milestones. Sandler highlighted the company's significant progress with its HEMO-CAR-T program after it received the green light from the US Food and Drug Administration (FDA) to enter Phase 1 clinical trials for acute myeloid leukaemia, marking its transition to a clinical-stage biopharmaceutical company. This development symbolises a pivotal milestone, offering potential life-changing treatments for patients with limited options. Additionally, Hemogenyx is advancing its proprietary Chimeric Bait Receptor (CBR) platform, announcing that it has demonstrated in vivo that the CBR can be delivered intranasally in the form of messenger RNA (mRNA) for the potential treatment of airborne viral infections. As 2024 unfolds, Hemogenyx anticipates starting clinical trials and advancing its CBR platform towards IND-enabling studies, signaling a landmark year with promising outcomes for investors and patients alike. Contact Details Proactive UK Ltd Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com
February 20, 2024 08:09 AM Eastern Standard Time
Video
News Release
hVIVO chairman Cathal Friel says he remains committed to hVIVO following share sale
hVIVO PLC
hVIVO chairman Cathal Friel joined Proactive's Stephen Gunnion to discuss the sale of shares in hVIVO PLC by directors, including himself. Friel explained his decision to sell a portion of his shares in hVIVO was to accommodate the high demand from major institutions while emphasising his commitment to remain a long-term, supportive shareholder despite this sale. Friel, who co-founded hVIVO (formerly known as Open Orphan) in 2017, highlighted the company's significant growth and his active involvement in its operations and strategic direction. He mentioned his 25-year experience in mergers and acquisitions (M&A) and his confidence in the company's ability to surpass its medium-term revenue target of £100 million, partly through strategic M&A activities. Additionally, Friel talked about his new role as Executive Chairman at Poolbeg, a company associated with hVIVO, assuring that this would not diminish his involvement with hVIVO. He shared his enthusiasm for the future of both companies, underscoring his role in identifying market opportunities and assembling high-performing teams to capitalize on them. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com
February 20, 2024 04:55 AM Eastern Standard Time
Video
News Release
Poolbeg Pharma chair discusses shift to executive role; hVIVO share sale
Poolbeg Pharma PLC
Poolbeg Pharma chairman Cathal Friel joined Proactive's Stephen Gunnion to discuss his new hands-on role at the company. Stepping up as the executive chairman at Poolbeg Pharma, Friel expressed his intention to replicate the success he achieved with hVIVO, another company he founded. With the addition of key former Amryt leadership team members to Poolbeg, Friel said he is optimistic about the company's aggressive growth prospects and is focused on share price appreciation. The chairman also explained the rational for the sale of shares in hVIVO PLC by directors, including himself. Friel, who has a rich background in mergers and acquisitions (M&A) and investment banking, said the decision was driven by strong institutional demand for hVIVO stock. Despite selling a small portion of his stake, he affirmed his long-term commitment to the company, highlighting its robust growth, profitability, and cash generation under current management. He also revealed plans to increase his stake in Poolbeg, indicating confidence in the company's potential and his commitment to driving shareholder value. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com
February 20, 2024 04:40 AM Eastern Standard Time
Video
News Release
Roberts & Ryan Inc., America's first Service-Disabled Veteran-Owned (SDVO) broker-dealer, is pleased to welcome Andrew Reynolds as Senior Director of Equity Trading.
Roberts & Ryan, Inc.
Andrew Reynolds joins Roberts & Ryan as Senior Director of Equity Trading and has more than 30 years of experience in equity trading, capital markets, portfolio management, options & derivatives, sales & business development, investor relations, and corporate compliance. Prior to joining Roberts & Ryan, Mr. Reynolds was Head of Equity Trading and a Registered Principal at Tullett Prebon and KCCI Ltd. Before that, he was Head Trader and Floor Broker at Tradition North America and R.J. Murphy & Associates. Prior to that, he was Head Trader at Preferred Technology. Mr. Reynolds began his career as an Options Clerk at Pershing, LLC. “Andrew brings extensive experience in equity trading and represents Roberts & Ryan’s commitment to providing best in class service and execution,” said James McDevitt, Roberts & Ryan’s Senior Director of Equity Sales and Trading, Capital Markets. “He will be a tremendous advocate for our social mission of supporting veterans and their families. I’m very excited to have him join our team.” Mr. Reynolds is a member of the Securities Traders Association (STA), the Securities Traders Association of New York (STANY), Philadelphia Traders (ITAP), and the National Investor Relations Institute (NIRI). He holds SIE and FINRA Series 7, 24, 25, 55, 57 & 63 licenses. Mr. Reynolds served as a Technical Warfare Specialist, Team Leader, and Group Leader in the 25 th Infantry Division of the United States Army and is a graduate of Archbishop Ryan in Philadelphia. About Roberts and Ryan, Inc. Roberts & Ryan, Inc. is a Service-Disabled Veteran Owned (SDVO) broker-dealer with execution capabilities in the capital markets, equities, and fixed-income trading. The firm was founded in 1987 by a United States Marine Corps Vietnam combat veteran and Purple Heart recipient. With over $1.8 million in committed donations, Roberts & Ryan is active in donating to charitable foundations that make significant positive impacts in the lives of Veterans and their families, focusing primarily on general wellness, mental health, and career transition. To learn more about Roberts & Ryan, please visit www.roberts-ryan.com. Contact Details Michael C. Del Priore +1 646-859-4061 mdelpriore@roberts-ryan.com Company Website https://www.roberts-ryan.com
February 19, 2024 09:00 AM Eastern Standard Time
Image
News Release
Kadimastem advances towards Nasdaq: Company Signs a Memorandum of Understanding to Merge with a Company traded on the Nasdaq
Kadimastem
Kadimastem Ltd. (TASE: KDST), a leading cell therapy company in the clinical development stages of breakthrough products for the treatment of ALS and diabetes, announces that the company has signed a non-binding agreement in principle (“MOU”) for a merger with a public company traded on the NASDAQ. pursuant to the MOU Kadimastem shareholders are expected to hold 88% of the shares of the combined company post -merger upon which Kadimastem will no longer be trading on the Tel Aviv Stock Exchange. The MOU is in line with the company's strategic plan, to approach the target markets of its field of activity and the US capital markets. As part of the terms of the MOU, Kadimastem undertook to have approximately $5 million in funds, including capital raised simultaneously with the completion of the transaction and the commencement of trading from existing shareholders and additional investors. Ronen Twito, Executive Chairman of the Board said, "Listing Kadimastem on the NASDAQ is an important and necessary goal for Kadimastem’s development and its progress to the company's target markets in the U.S., as we have stated in the past. The MOU is an important step in that direction. It follows the Company's report of receipt of FDA approval for a Phase IIa multi-site clinical trial in the US for the treatment of ALS, and the joint development agreement signed with iTolerance Inc., a Florida based company with a product in the field of diabetes which we recently reported to have a successful joint INTERCT meeting with the FDA.” We believe that the exposure to the U.S. capital markets will assist Kadimastem in the development of the company's clinical assets and preparations for the planned multi-site clinical trial for the US, and as a result will create value for the company's shareholders." About Kadimastem Kadimastem is a clinical stage cell therapy company, developing "off-the-shelf", allogeneic, proprietary cell products based on its technology platform for the expansion and differentiation of Human Embryonic Stem Cells (hESCs) into functional cells. AstroRx®, the company's lead product, is an astrocyte cell therapy in clinical development for the treatment for ALS and in pre-clinical studies for other neurodegenerative indications. IsletRx is the company's treatment for diabetes. IsletRx is comprised of functional pancreatic islet cells producing and releasing insulin and glucagon, intended to treat and potentially cure patients with insulin-dependent diabetes. Kadimastem was founded by Professor Michel Revel, CSO of the company and Professor Emeritus of Molecular Genetics at the Weizmann Institute of Science. Professor Revel received the Israel Prize for the invention and development of Rebif®, a multiple sclerosis blockbuster drug sold worldwide. Kadimastem is traded on the Tel Aviv Stock Exchange (TASE: KDST). Social Media: LinkedIn, Twitter, Facebook Kadimastem (TASE:KDST) is a clinical stage biotechnology company, with a unique platform for cell therapy that enables the production of off-the-shelf cell-based products for the treatment of unmet medical needs. Kadimastem was founded in 2009 based on patent protected technology that was developed at Prof. Michel Revel’s laboratory at the Weizmann Institute of Science. Forward Looking Statement This document may include forward-looking information as defined in the Securities Law, 5728 – 1968. Forward-looking information is uncertain and mostly is not under the Company's control and the realization or non-realization of forward-looking information will be affected, among other things, by the risk factors characterizing the Company's activity, as well as developments in the general environment and external factors affecting the Company's activity. The Company's results and achievements in the future may differ materially from any presented herein and the Company makes no undertaking to update or revise such projection or estimate and does not undertake to update this document. This document does not constitute a proposal to purchase the Company's securities or an invitation to receive such offers. Investment in securities in general and in the Company in particular bears risks. One should consider that past performance does not necessarily indicate performance in the future. Contact Details Kadimastem Ltd. Asaf Shiloni +972 73-797-1613 s.bazak@kadimastem.com Company Website https://www.kadimastem.com/
February 16, 2024 07:00 AM Eastern Standard Time
Image
